23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

23andMe reports strong Q1 growth, focuses on profitability and partnerships

23andMe demonstrated strong growth in customer base and subscription members, with a focus on margin expansion and revenue growth. The company faces challenges in achieving profitability but has opportunities to leverage genetics for healthcare transformation and pursue partnerships. Overall, 23andMe's performance reflects a strategic focus on growth and financial discipline.

23andMe reports Q1 revenue decline, focuses on therapeutics and AI

Despite a decrease in Q1 2023 revenue, 23andMe demonstrated strength in its therapeutics business and strategic pricing initiatives. The company faces challenges with significant workforce reduction and higher operating expenses but has opportunities in advancing immuno-oncology assets and leveraging AI advancements.

23andMe reports revenue growth and strategic initiatives for future expansion

Overall, 23andMe's Q3 performance showcased growth and innovation in both consumer and therapeutic segments. While facing challenges with increased expenses and a net loss, the company's raised full-year guidance and strategic initiatives present opportunities for future expansion and profitability.

23andMe reports revenue growth and strategic healthcare integration plans

23andMe's Q4 2023 earnings call showcased strong revenue growth, new health report offerings, and advancements in therapeutics. Despite financial projections indicating a net loss and EBITDA deficit for FY 2024, the company remains focused on expanding margins and capital efficiency. Integration of telehealth services and personalized care present promising opportunities for future growth.

23andMe reports Q1 revenue decline, eyes growth in therapeutics

23andMe navigated challenges with workforce reductions and revenue decline, focusing on margin improvement and cost discipline. The company aims to capitalize on opportunities in therapeutics and consumer businesses through strategic initiatives. With a strong cash position and guidance for improvement in adjusted EBITDA deficit, 23andMe is positioning for future growth.

23andMe reports Q2 revenue of $50M, focuses on margin expansion

23andMe's Q2 2024 performance showed revenue of $50 million with a net loss of $75 million, emphasizing margin expansion.
Strengths include new subscription offerings, FDA clearances, promising therapeutics pipeline, and data security focus.
Challenges include net losses, adjusted EBITDA deficit, and updated FY 2024 guidance reflecting uncertainties.
Opportunities lie in expanding subscription services, enhancing product offerings, and leveraging collaborations for growth.

23andMe reports Q3 revenue decline, focuses on strategic growth

23andMe faced revenue decline and increased expenses, leading to a significant net loss and revised guidance for fiscal year 2024.
Despite challenges, the company showcased strengths in strategic progress, therapeutics advancements, and extended collaborations.
Opportunities lie in margin expansion, cash flow profitability, and leveraging consumer offerings and partnerships for future growth.

23andMe reports strong revenue growth and strategic shifts for growth

23andMe showcased strong performance in membership revenue growth and advancements in research and therapeutics, despite challenges in revenue and operating expenses.
The company's strategic shift towards high-value programs and partnerships with GSK position it well for long-term growth and innovation in the genetic testing and healthcare space.
While facing challenges in cost management and revenue generation, 23andMe has opportunities to optimize operations, drive growth through new programs, and address compliance issues.
Overall, 23andMe's focus on innovation, strategic collaborations, and operational efficiency sets the stage for navigating challenges and capitalizing on growth opportunities in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

Last week's good news for the genetic data miner wasn't as good as it looked.

Why 23andMe Stock Crashed 10% Today

23andMe lost a lot less money than feared today -- so why is it sticking with a prediction for a full-sized loss for the year?

Why 23andMe Stock Scored an 11% Gain Today

23andMe Holding Co. (ME) CEO Anne Wojcicki on Q2 2021 Results - Earnings Call Transcript

Second quarter revenue of $55 million Recent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives

23andMe Reports FY2022 Second Quarter Financial Results

SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, announced today that management will be presenting at three upcoming virtual investor conferences: Credit Suisse 30th Annual Healthcare Conference on Thursday, November 11 at 12:10 pm ET Piper Sandler 33rd Annual Healthcare Conference.

23andMe to Present at Upcoming Virtual Healthcare Conferences

SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, today announced the appointment of Dr. Sandra Hernández, President & CEO of the California Health Care Foundation ("CHCF"), to its Board of Directors.

23andMe Announces Appointment of Dr. Sandra Hernández to Board of Directors

Coinbase

Plug Power

Nearly 500 companies are reporting quarterly earnings this week. The one in our watch list for Monday morning, Coty, beat estimates on both the top and bottom lines.

Earnings Previews: Coinbase, Nio, Plug Power, 23andMe

SUNNYVALE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 second quarter after market closes on Wednesday, November 10, 2021.

23andMe Provides Updated Timing for FY2022 Second Quarter Financial Results and Announces New Online Q&A Platform for Shareholders

The genetics upstart is acquiring a telehealth platform.

Why 23andMe Rocketed 27.9% Higher in October

SUNNYVALE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it has completed its previously-announced acquisition of Lemonaid Health, Inc. (“Lemonaid Health”), an on-demand platform for accessing medical care and pharmacy services online.

23andMe Announces the Closing of its Acquisition of Lemonaid Health

Investors may see potential in the company's proposed acquisition of telehealth company Lemonaid.

Why 23andMe Stock Was Up More Than 9% on Tuesday

Hims & Hers Health has had its biggest one-day loss in over two months, following its rival 23andMe's agreement to buy web-based healthcare platform Lemonaid Health. Hims & Hers is a telehealth platform working on custom health and wellness in multi-specialty needs.

23andMe to Buy Web Platform Lemonaid Health for $400M

Fresh off its SPAC IPO, 23andMe is buying another company.

Why 23andMe Stock Dropped Today

Direct-to-consumer DNA testing firm 23andMe Holding Co said on Friday it would buy privately held company Lemonaid Health Inc for $400 million in a cash-and-stock deal, as it looks to expand into telemedicine.

23andMe to buy telehealth firm Lemonaid for $400 million

23andMe Holding Co. ME, +1.27% said Friday it agreed to pay $400 million for Lemonaid Health Inc., the on-demand platform for accessing medical care and pharmacy services, in a bid to add telemedicine and prescription drug delivery services. The purchase price includes 25% cash and 75% in shares of 23andMe Class A common stock.

23andMe buys telemedicine specialist Lemonaid Health

Acquisition provides telemedicine platform for 23andMe to advance its vision of individualized primary care that empowers consumers to live healthier lives

23andMe Agrees to Acquire Lemonaid Health

A favorable mention on CNBC lit a fire underneath the biotech's stock this week.

Why 23andMe Stock Has Jumped 16% So Far This Week

SUNNYVALE, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 second quarter before the market opens on Wednesday, November 10, 2021. The Company will webcast a conference call at 4:30 p.m. Eastern Time to discuss the quarter's financial results and report on business progress.

23andMe to Report FY2022 Second Quarter Financial Results on November 10, 2021

It needs to make money from something bigger than just its genetic test kits.

23andMe Stock Could Be a Big Winner If This 1 Thing Happens

23andMe (ME) stock is running higher on Friday as investors pile on with heavy trading thanks to a recent interview on CNBC. The post ME Stock: 6 Things to Know About 23andMe as Shares Shoot Higher Today appeared first on InvestorPlace.

ME Stock: 6 Things to Know About 23andMe as Shares Shoot Higher Today

An analyst calls 23andMe's 11 million sample database unique and unprecedented.

Why 23andMe Stock Jumped 16% Today

23andMe is well known for their services around DNA testing, ancestry mapping, and genetic data. By collaborating with GlaxoSmithKline, the companies can better use 23andMe's 11.6 million genotyped customer database to develop beneficial drugs.

23andMe Stock: Continued Drug-Development Progress Can Deliver Long-Term Gains

Despite losing millions right now, this company could have massive long-term growth potential.

Here's Why I Bought This Recent Genetics IPO

Austerlitz Acquisition Corporation I

AvePoint

Fisker Inc

Hyzon Motors

Microvast Holdings

TPG Pace Beneficial Finance Corp.

The billionaire's blank-check company proved to be a bust, but these seven other SPACs still have a shot at becoming long-term winners. The post 7 SPACs to Buy That Are Better Than Bill Ackman's Pershing Square Tontine appeared first on InvestorPlace.

7 SPACs to Buy That Are Better Than Bill Ackman's Pershing Square Tontine

MercadoLibre

Offerpad Solutions

These aren't exactly low-risk stocks, but the long-term potential could be enormous.

News for 23andMe Stock (ME)